Percutaneous ablation: treating tumours and pain without open surgery

Percutaneous ablation is the image-guided destruction of unwanted tissue — usually a tumour, sometimes a source of chronic pain — using heat, cold, chemicals, or electrical energy, delivered through a needle-sized probe rather than an open incision. It's performed under CT, ultrasound or MRI guidance, and for many patients it's a day procedure with a far shorter recovery than surgery.

Why choose ablation over surgery?

Ablation isn't a replacement for surgery in every situation, but it offers real advantages for the right patient and the right lesion: lower morbidity, a shorter hospital stay, lower cost, and the ability to treat someone who might not tolerate a general anaesthetic or major operation. It's typically best suited to small, unresectable tumours, or to patients who are poor surgical candidates for other health reasons.

The trade-off is precision under pressure: the real technical challenge in any ablation is achieving complete coverage of the tumour with a safe margin, particularly when the lesion sits near a major vessel, airway, or other structure that limits how aggressively it can be treated.

What actually kills the tissue?

Every ablation technique works by pushing tissue past the point where its cells can survive — through extreme heat, extreme cold, an electrical field, or a caustic chemical. In heat-based ablation, tissue temperature above roughly 60°C causes rapid protein breakdown and cell death. Directly around the probe, this produces irreversible coagulative necrosis; further out, cells experience sub-lethal injury that may recover or undergo delayed cell death; beyond that, tissue is largely unaffected. This is why probe placement and coverage planning matter so much — the "kill zone" has a centre, an edge, and a margin of uncertainty.

Cold-based ablation (cryoablation) works differently and is discussed in more detail below, since it has some distinct practical advantages that are worth understanding on their own.

The main ablation techniques

Radiofrequency ablation (RFA)

An electrode is placed directly into the tumour under ultrasound or CT guidance. An alternating electrical current passes through the tissue, generating heat through resistance — reaching effective temperatures of roughly 60–100°C. RFA is one of the longest-established and most cost-effective ablation techniques, particularly for smaller tumours.

Its main limitation is the heat-sink effect: blood flowing through vessels near the tumour carries heat away from the target faster than the electrode can replace it, which can leave viable tumour tissue at the margin closest to a vessel. RFA is generally more affected by this than microwave ablation. Tissue can also dry out (desiccate) above 100°C, which limits how much further heating is possible in a single application.

Microwave ablation (MWA)

An antenna delivers electromagnetic energy — typically in the 900–2450 MHz range — causing water molecules in the tissue to oscillate and generate heat directly (dielectric heating), rather than relying on electrical conduction through the tissue itself. This generally produces faster, larger, and more evenly distributed heating than RFA, and is considerably less affected by the heat-sink effect. It's often the preferred choice for larger tumours or higher-resistance tissue types like lung and bone. The trade-off is bulkier equipment and a need to manage the risk of antenna overheating.

Cryoablation

Cryoablation destroys tissue by freezing it rather than heating it, using a probe cooled by the Joule–Thomson effect (high-pressure argon gas expanding rapidly at the probe tip drops the temperature sharply; helium is used to thaw). It's now commonly used for kidney, liver, lung, prostate and breast lesions, and — like the other techniques — is usually performed percutaneously under image guidance.

Cell death happens through two separate mechanisms. Direct injury comes from ice crystals forming both inside and around cells, which physically damages membranes and organelles and disrupts the cell's internal chemistry; a second wave of damage often happens during thawing, as osmotic swelling and further ice crystal growth rupture already-weakened cells. Indirect injury comes from the freeze damaging nearby blood vessels, triggering clot formation and cutting off blood supply to the treated area, which starves any surviving tissue.

Reliable tumour kill is generally targeted at around −20°C to −40°C, and both the freezing and the thawing phases contribute to the final result — which is part of why repeated freeze–thaw cycles are often used rather than a single freeze.

Cryoablation has a few practical advantages worth knowing about. The "ice ball" it forms is directly visible on ultrasound, CT and MRI in real time, which gives the treating physician a level of visual feedback that heat-based methods don't offer as clearly — the visible edge of the ice ball corresponds closely to the 0°C boundary, though reliable cell death actually happens well inside that visible edge. Freezing also has a natural anaesthetic effect on tissue, so cryoablation is often better tolerated than heat-based methods and can frequently be done under moderate sedation rather than a general anaesthetic. Multiple probes can be used together to shape the treatment zone around an irregular tumour.

Chemical ablation

The simplest technique: a chemical agent — most often concentrated ethanol, sometimes acetic acid — is injected directly into the tumour, causing cellular dehydration, protein breakdown, and vascular clotting. It's cheap, technically straightforward, and remains a well-established option for small hepatocellular carcinoma (a type of liver cancer). Its main limitation is that it often needs multiple treatment sessions and doesn't distribute evenly through larger or internally divided (septated) tumours.

High-intensity focused ultrasound (HIFU)

HIFU is the only technique here that doesn't require inserting a probe into the body at all — focused ultrasound energy is aimed at the tumour from outside, under ultrasound or MRI guidance, rapidly raising the tissue temperature above roughly 55°C at the focal point. Its advantage is being genuinely incisionless with sharp targeting; its limitations are longer treatment times, the need for a clear "acoustic window" to the target (some locations in the body simply can't be reached effectively), and more limited availability compared to needle-based techniques.

Irreversible electroporation (IRE)

IRE uses short, high-voltage electrical pulses to punch permanent nanoscale pores in cell membranes, causing cell death without relying primarily on heat or cold. Because it doesn't rely on thermal injury, it can sometimes be used closer to structures like bile ducts or major vessels that would otherwise be at risk from a heat- or cold-based technique's margin — and because it's non-thermal, it isn't affected by the heat-sink effect the way RFA is.

Quick comparison

Ablation for pain, not just tumours

Ablation isn't only an oncology tool. The same image-guided, heat- or cold-based approach can be used to target specific nerves, ganglia, or soft-tissue pain generators — for example in certain chronic musculoskeletal or cancer-related pain conditions, including pain arising from a tumour pressing on or invading nearby structures such as bone. In that context, the goal isn't to cure the underlying disease but to interrupt or reduce a specific, localised source of pain, often when other pain management approaches haven't given enough relief.

A note on the immune system

There's a growing body of research into how ablation affects the immune system beyond the treatment site itself. When ablation destroys tumour cells, it can release tumour antigens and other "danger signals" that draw the immune system's attention — and there are documented cases of untreated tumours elsewhere in the body shrinking after a different lesion was ablated, suggesting a broader immune response can sometimes be triggered locally. On its own, this effect is usually not strong enough to eliminate established disease, but there's active research interest in deliberately combining ablation with immunotherapy — checkpoint inhibitors, dendritic cell vaccination, and similar approaches — to try to turn a local treatment into a more systemic one. This remains an evolving area rather than routine practice.

What to expect

Most ablation procedures are performed as day cases. You'll typically have imaging beforehand to plan the approach, the procedure itself under local anaesthetic with sedation (occasionally general anaesthetic, depending on the technique, location, and your own health), and a period of monitoring afterward before going home. Follow-up imaging at set intervals afterward checks that the treated area has responded as expected and that there's no sign of recurrence at the margin.

• Bodard S, et al. Percutaneous cryoablation in soft tissue tumor management: an educational review. Insights Imaging. 2024;15(1).
• Dai R, Uppot R, Arellano R, Kalva S. Image-guided ablative procedures. Clin Oncol (R Coll Radiol). 2024;36(8):484-497.
• Campbell WA IV, Makary MS. Advances in image-guided ablation therapies for solid tumors. Cancers (Basel). 2024;16(14):2560.
• Mustafa AR, Miyasato D, Wehrenberg-Klee E. Synergizing thermal ablation modalities with immunotherapy. J Vasc Interv Radiol. 2024;35(2):185-197.
• Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011;258(2):351-369.
• Slovak R, et al. Immuno-thermal ablations — boosting the anticancer immune response. J Immunother Cancer. 2017;5(1):78.
• Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms. Cryobiology. 2009;58(1):1-11.